Mobile med tech connection platform Validic gets $5M; Tattoo turns sweat into electricity;

@FierceMedDev: ICYMI: Here's yesterday's issue of FierceDrugDelivery. | Follow @FierceMedDev

@StacyALawrence: You're so fierce: A call for nominations of the top women in med tech. Editor's corner | Follow @StacyALawrence

@VarunSaxena2: Big VC scoop from my colleague : Sofinnova spinoff HealthQuest targets $110M, makes first investments. News | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Medicated electrospun fabric offers alternative delivery method for HIV-preventing drugs. FierceDrugDelivery story | Follow @EmilyWFierce

> Validic, a mobile healthcare device connection platform, closed a Series A investment round with $5 million raised. More

> Researchers at the University of California, San Diego, created a temporary tattoo that can turn the wearer's sweat into a modest electrical current. More

> Harvard University's endowment invested in 400,000 shares of Covidien ($COV) stock before news of the Medtronic ($MDT) merger was made public. More

Biotech News

@FierceBiotech: Merck wins FDA nod for a weaker form of its embattled sleep drug. Article | Follow @FierceBiotech

@DamianFierce: ICYMI yesterday: $MRK's suvorexant will sell as Belsomra, but dosing issue will likely limit its market value. Article | Follow @DamianFierce

@EmilyMFierce: Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors. Story | Follow @EmilyMFierce

> InterMune buyout rumors resurface, with Roche, Sanofi on the short list. More

> Allergan bets up to $588M on Taris' bladder candidate. News

> Prefer a Swiss tax rate? Basilea chief says he's ready to parley. Story

> AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown. Article

Pharma News

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Want more? Subscribe here. | Follow @FiercePharma

@EricPFierce: ICYMI yesterday: Merck KGaA has to rely on AZ as its pharma sales contract in Q2. Article | Follow @EricPFierce

@CarlyHFierce: Sovaldi payer pushback hurting access for opioid treatment patients. Story | Follow @CarlyHFierce

> InterMune takeover talk is tantalizing, but are investors too optimistic? Report

> Merck's sleep drug suvorexant overcomes hurdles to win FDA approval. Article

> The irrational rationale for cancer drug prices, with Novartis' Zykadia as exhibit A. Story

Vaccines News

> Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors. More

> Researchers retract narcolepsy study linked to Glaxo's Pandemrix. Report

> Health Canada signs off on GSK's plans to improve its flu vaccine plant. More

> Pfizer's Prevnar gets $2B boost with CDC nod in older adults. Article

> Dendreon's debt plans could leave stockholders in the lurch. Story

Pharma Manufacturing News

> Shire takes over production of Buccolam after contractor fails. Article

> Amgen recalls Aranesp syringes contaminated with polyester. Report

> Indian regulator lays down new standards for its inspectors. More

> Baxter recalls another lot of saline solution as shortage persists. Story

> Canada says GSK flu vaccine plant is on track; the FDA remains mum. Item

> Wockhardt's run-ins with the FDA cost it most of its profits for a quarter. Article

Suggested Articles

J.D. Power aims to set the benchmarks in telehealth satisfaction with a new study due this November.

Atomwise plans to screen up to 10 billion virtual compounds for therapies against childhood cancer in collaboration with chemical supplier Enamine.

The Chan Zuckerberg Initiative set aside $68 million for over three dozen projects in an effort to map out every type of cell in the body.